Drug intelligence / Profile preview

LMN-GI-EEC-401

Development stage: Phase 1
Lead developer: Lumen Bioscience
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Oral

Overview

LMN-GI-EEC-401, also referred to in a registered clinical study as LMN-401, is an investigational oral monoclonal-antibody cocktail developed by Lumen Bioscience for prevention of traveller's diarrhea and other diarrheal illnesses associated with *Campylobacter jejuni* and enterotoxigenic *Escherichia coli*. The product is manufactured using Lumen's spirulina-expression platform and is intended to provide a low-cost, room-temperature-stable, orally delivered antibiotic-alternative biologic. Its specific antibody component identities and molecular antigen targets have not been publicly disclosed. ([carb-x.org](https://carb-x.org/gallery/lumen-bioscience/))

Other names: LMN GI EEC 401

Beyond the preview

Go deeper on LMN-GI-EEC-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LMN-GI-EEC-401.

Explore the full profile